This article is more than 5 years old. Information may no longer be current.
PDT, high-dose triamcinolone to treat AMD, study shows
Click Here to Manage Email Alerts
Combining photodynamic therapy with high-dose intravitreal triamcinolone acetonide for treating age-related macular degeneration improves visual acuity and reduces retreatment need, according to a study.
Jose Ruiz-Moreno, MD, and colleagues conducted the prospective, comparative, nonrandomized interventional case series, which involved 30 consecutive eyes of 30 patients with subfoveal choroidal neovascularization associated with AMD. The researchers divided patients into two groups; Group 1 had 15 eyes that received no previous treatment, and group 2 had 15 eyes that were treated previously with PDT. Fifteen eyes in 15 patients treated with PDT alone served as controls.
Patients in groups 1 and 2 were treated with PDT followed by an injection of 19.4 ± 2.1 mg/0.1 mL triamcinolone 5 days later. The researchers found that patients in group 1 improved an average of 0.7 ± 1.5 lines (P = .62), and patients in group 2 lost an average of –0.7 ± 1.5 lines (P = .08). The control group lost an average of –2.2 ± 0.4 lines (P = .06), according to the study.
IOP increased in eight of 14 eyes in group 1 (57%) and in seven of 14 eyes in group 2 (50%). Four eyes in group 1 (31%) and four eyes in group 2 (33%) also developed cataracts.
The study was published in the July/August issue the Journal of Retina and Vitreous Diseases.